![\"\"](\"https:\/\/icrowdnewswire.com\/wp-content\/uploads\/2020\/06\/3998-logo-160.png\"){kind=logo}
<\/p>\n<\/p>\n
![\"Mark](\"https:\/\/www.siliconrepublic.com\/wp-content\/uploads\/2020\/06\/Mark-Barrett-718x523.jpg\")
<\/div>\nIrish-based pharma research firm APC has announced a partnership with Australian biotech company Vaxine to help develop a Covid-19 vaccine candidate.<\/p>\n
A new partnership will see a promising Covid-19 vaccine candidate be developed here in Ireland. Pharma research company APC announced today (10 June) that it has signed a partnership with the Australian biotech company Vaxine.<\/p>\n
This partnership aims to accelerate the development and launch of a Covid-19 vaccine using facilities at APC’s Dublin headquarters. The APC site is currently developing more than 20 other medicines for a variety of conditions including cancers, respiratory diseases, Alzheimer’s disease and HIV.<\/p>\n
APC currently employs a team of 130 people, the majority of which are chemical engineers, process and biopharmaceutical scientists.<\/p>\n
Adelaide-headquartered Vaxine revealed earlier this year that it has developed one of the first protein-based Covid-19 vaccine candidates to achieve preclinical testing. It combines an insect cell produced recombinant spike protein antigen with Vaxine’s Advax-SM adjuvant turbocharger. The company said animal immunogenicity studies have confirmed the effectiveness of this combination.<\/p>\n
Commenting on this new partnership, APC CEO Dr Mark Barrett said: “Never before has the combination of novel vaccine and processing sciences been so important to the world.<\/p>\n
“Today through this strategic partnership, APC and Vaxine signify our collective intent to combine the latest innovation in Covid-19 vaccine technology and processing sciences, BioAchieve, to accelerate the development and launch of Vaxine’s novel Covax-19 vaccine.”<\/p>\n
Meanwhile, Vaxine’s chair and research director, Nikolai Petrovsky, added: “Following completion of clinical trials, which are currently being initiated, Vaxine wishes to make its Covax-19 vaccine available to as many countries of the world as possible.<\/p>\n
“There is an extraordinary unmet demand for effective and safe Covid-19 vaccines. By partnering with professional process development companies such as APC, who can assist with large scale process and technology design; optimisation and technology transfer, it will assist us in meeting such demand.”<\/p>\n
Vaxine said that following human trials and further testing, it hopes to have a commercial launch of a Covid-19 vaccine early next year.<\/p>\n<\/div>\n<\/div>\n<\/div>\n
Tags:<\/b> Colm Gorey<\/p>\n<\/p><\/div>\n","protected":false},"excerpt":{"rendered":"
<\/a>, Wire<\/a>, United States<\/a>, English<\/a><\/p>\n<\/div>\n
\nContact Information:<\/h3>\n
Irish-based pharma research firm APC has announced a partnership with Australian biotech company Vaxine to help develop a Covid-19 vaccine candidate. A new partnership will see a promising Covid-19 vaccine candidate be developed here in Ireland. Pharma research company APC announced today (10 June) that it has signed a partnership with the Australian biotech company … Continue reading APC announces new partnership to help develop Covid-19 vaccine in Ireland<\/span><\/a> Continue Reading